Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetylcysteine and integrated preventive psychological intervention for prevention of first psychotic episode in people at clinical high risk
2014-003076-22Phase 3Completed
- Sponsor
- Central Institute of Mental Health
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of acetylcysteine in Schizophrenia Spectrum Disorders (SSD) (4 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Transition to psychosis within up to 18 months. Started Nov 2015; status: completed.
02
Drugs
acetylcysteine
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2014-003076-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003076-22.